Bambusa IPO Brings In $169M to Break Immunology’s ‘Therapeutic Ceiling’

Coverage, in order

1. 12d ago
   
   MedCity News indie study

   Bambusa IPO Brings In $169M to Break Immunology’s ‘Therapeutic Ceiling’

   Bambusa Therapeutics’ IPO cash will support its pipeline of bispecific antibodies designed to offer advantages over currently available monoclonal antibodies. Aspen Neuroscience also debuted on the Nasdaq as it prepares for a pivotal test of its Parkinson’s disease cell therapy.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.